Intensity modulated radiation therapy or stereotactic fractionated radiotherapy for infratentorial ependymoma in children: a multicentric study by Weber, Damien et al.
CLINICAL STUDY – PATIENT STUDY
Intensity modulated radiation therapy or stereotactic fractionated
radiotherapy for infratentorial ependymoma in children:
a multicentric study
Damien C. Weber • Thomas Zilli • Hans Peter Do •
Philippe Nouet • Fabienne Gumy Pause •
Alessia Pica
Received: 30 April 2010 / Accepted: 19 July 2010 / Published online: 20 August 2010
 Springer Science+Business Media, LLC. 2010
Abstract This study was to evaluate the treatment dosim-
etry, efficacy and toxicity of intensity modulated radiation
therapy (IMRT) and fractionated stereotactic radiotherapy
(FSRT) in the management of infratentorial ependymoma.
Between 1999 and 2007, seven children (median age,
3.1 years) with infratentorial ependymoma were planned with
either IMRT (3 patients) or SFRT (4 patients), the latter after
conventional posterior fossa irradiation. Two children
underwent gross total resection. Median prescribed dose was
59.4 Gy (range, 55.8–60). The median follow-up for surviv-
ing patients was 4.8 years (range, 1.3–8). IMRT (median
dose, 59.4 Gy) and FSRT (median dose, 55.8 Gy) achieved
similar optimal target coverage. Percentages of maximum
doses delivered to the cochleae (59.5 vs 85.0% Gy; P = 0.05)
were significantly inferior with IMRT, when compared to
FSRT planning. Percentages of maximum doses administered
to the pituitary gland (38.2 vs 20.1%; P = 0.05) and optic
chiasm (38.1 vs 14.1%; P = 0.001) were, however, signifi-
cantly higher with IMRT, when compared to FSRT planning.
No recurrences were observed at the last follow-up. The esti-
mated 3-year progression-free survival and overall survival
were 87.5 and 100%, respectively. No grade [1 acute toxicity
was observed. Two patients presented late adverse events
(grade 2 hypoacousia) during follow-up, without cognitive
impairment. IMRT or FSRT for infratentorial ependymomas
is effective and associated with a tolerable toxicity level. Both
treatment techniques were able to capitalize their intrinsic
conformal ability to deliver high-dose radiation. Larger series
of patients treated with these two modalities will be necessary
to more fully evaluate these delivery techniques.
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Introduction
Ependymomas accounts approximately for 8–10% of all
childhood CNS tumors and the mean age at diagnosis
ranges from 50 to 70 months [1–4]. They are of neuroec-
todermal origin arising from ependymal cells in the oblit-
erated central canal of the spinal cord, the filum terminale,
choroid plexus or white matter adjacent to the highly
angulated ventricular surface [5]. The majority of these
tumors are of infratentorial location, particularly in the
fourth ventricle [6].
Ependymoma is a rare tumor with fewer than 170 new
cases diagnosed in the United States each year [7] and its
treatment is somewhat controversial, including a multim-
odality approach, consisting of surgery, radiotherapy and
chemotherapy.
Complete surgical resection appears to be the most
important factor for children with ependymoma [8–11].
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Craniospinal irradiation has been utilized in the past as
standard approach in the management of infratentorial
ependymomas [12], but has been progressively replaced by
a more localized radiation fields, including the posterior
fossa [13] or volumes limited to pre-surgical tumor bed
with an added margin of 1–2 cm [14]. Reducing the dose of
radiation administered to the organs at risks (OARs) and to
the normal developing brain is a logical approach for
treating pediatric ependymomas. As such, the use of non-
conventional radiation therapy (RT), including intensity-
modulated RT (IMRT) or fractionated stereotactic RT
(FSRT), allows one to achieve significant improvements in
dose distributions when compared to 3D conformal RT. No
comparative study has assessed the dose distribution of
IMRT compared to FSRT techniques.
In this study, we first analyzed the dose deposition of
these two delivery techniques. Secondly, we assessed the
acute and late toxicity of IMRT and FSRT. Lastly, we
analyzed the outcome of these patients.
Materials and methods
From 1999 to 2007, a total of seven patients with resected
infratentorial ependymoma were planned at the University
Hospital of Geneva (3 patients) and Lausanne (4 patients)
with postoperative IMRT and FSRT boost after posterior
fossa irradiation, respectively. The patients’ characteristics
are detailed in Table 1.
Presenting symptoms and signs were nausea and vom-
iting in seven, ataxia in four, headache in two, and nys-
tagmus and vertigo in one patient. Visual disturbance
associated with memory and cognitive impairment was
found in one patient. The majority of patients were neu-
rologically unimpaired.
Staging consisted of magnetic resonance imaging (MRI)
of the entire central nervous system. Cytological exami-
nation of the cerebrospinal fluid (preoperative, n = 2;
postoperative, n = 5) was done in all patients. No patients
had M? disease during the time of diagnosis. One patient,
however, presented with a metastatic progression before
the start of IMRT, documented on a spinal MRI. Based on
the operative reports and postoperative MRI, two and five
patients had gross total resection and subtotal resection,
respectively. Pathology was World Health Organization
(WHO) grade II and III in six and one patients, respec-
tively. Two patients received chemotherapy according to
the institutional open protocols. No concomitant chemo-
therapy was delivered during RT.
Target volume consisted on the preoperative gross
tumor volume (GTV) delineated on the preoperative MRI,
which was fused with the planning CT. For FRST boost, a
4-mm 3D anisotropic margin was added to the GTV,
defining the planning target volume (PTV). For IMRT, the
CTV was defined by the GTV ? 15-mm margin and the
PTV was and additional 5-mm margin beyond the CTV.
Three patients were planned at University of Geneva for
IMRT using a 6-MV dedicated multileaf collimator linear
accelerator (CLINAC 2100-C; Varian Medical System,
Palo Alto, CA). An IMRT technique employing five or
seven coplanar fields was adopted to deliver a median dose
of 59.4 Gy (range, 59.4–60) in 1.8 or 2 Gy/daily fraction.
Four patients were planned at University of Lausanne
for FSRT boost after conventional PF irradiation. A Brain-
LAB multileaf collimator linac (BrainLAB, Fieldkirchen,
Germany) was utilized for treatment delivery. Four or five
isocentric non-coplanar fields were utilized as a boost to
Table 1 Patient demographics and tumor characteristics (n = 7)
n %
Age (years)
Median 3.1
Range 1.5–9.9
Age (years)
\4 5 71
C4 2 29
Gender
Male 4 57
Female 3 43
KPS
100 3 43
90 2 29
80 1 14
50 1 14
NFS
0 2 28
1 3 43
2 1 14
4 1 14
Histology type (WHO)
II 6 86
III 1 14
Surgery
GTR 2 29
STR 5 71
Chemotherapy
Yes 2 29
No 5 71
Follow-up after RT (years)
Median 4.8
Range 1.3–8
KPS Karnofsky Performance Index, NFS Neurological Function
Scale, WHO World Health Organization, GTR gross total resection,
STR subtotal resection
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deliver to target volume a total dose ranged from 55.8 to
59.4 Gy (median, 55.8). PF was treated with conventional
3D external beam radiotherapy (EBRT) using two lateral
opposed fields with a median dose of 46.8 cGy (range,
36–50.4) in 1.8 Gy daily fractions delivered with 6- or 18-
MV photons of a multileaf standard accelerator. Median
FSRT boost dose to the local field was 9 Gy (range,
5.4–23.4).
Median time to radiation treatment start was 38 days.
Five patients \4 years old (2 and 3 in IMRT and FSRT
groups, respectively) required general anaesthesia during
simulation and the RT delivery. Daily setup position was
verified using portal images matched with digitally recon-
structed radiographs for patients treated with IMRT, while
for those treated with FSRT, the stereotactic setup was
based on an infrared guided repositioning device with the
patient immobilized in a customized mask attached to a
non-invasive stereotactic localization frame with an overall
geometrical uncertainity of 1–2 mm.
Patients were followed weekly during the treatment
course and with a visit at 6 weeks after completion of RT,
then regularly every at 3- or 6-month intervals with clinical
examination and MRI of the brain every 4 months during the
first 2 years and every 6 months successively. The median
follow-up for surviving patients was 4.8 years (range, 1.3–8)
after RT start.
Acute and late side effects were evaluated using the
Common Toxicity Criteria (CTCAE) Version 3.0 grading
system (http://www.ctep.cancer.gov). Acute toxicity was
defined as side effects occurring during treatment or within
90 days after NCRT completion. Neurocognitive testing
was performed at the baseline and then regularly after the
start of RT.
Progression-free survival (PFS) and overall survival
(OS) were calculated from the date of the first day of RT
using Kaplan–Meier estimates. The events were death (all
causes of death included) for OS and progressive disease or
death for PFS. Progressive disease was defined as treatment
failure occurring locally (PF) and/or distantly (spine or/and
brain). Differences between the FSRT and IMRT percent-
ages of prescribed doses were calculated using the two-
sided Student-t test. The statistical analysis was performed
on the SAS system (Ver. 5.0; SAS, Chicago, IL).
Results
Dosimetric characteristics
Treatment characteristics and dosimetric results of IMRT
and FSRT are summarized in Tables 2 and 3. Optimal target
volume coverage was obtained with both techniques. The
percentage of the prescribed GTV mean dose was similar
with IMRT and FSRT (100.5 and 100.3%, respectively).
Patients planned with IMRT received however significantly
(P = 0.05) more monitor units (MU) for treatment delivery
(median, 594 MU) than those planned with FSRT (median,
498 MU).
Comparing IMRT and FSRT, the mean percentage of
maximum dose delivered to OARs was significantly
lower with FSRT for the pituitary gland and optic chiasm
(Table 3). Conversely, a lower mean percentage of max-
imum dose to the cochleae was observed with IMRT
when compared to SFRT planning (Table 3). Likewise,
the mean percentage of maximum dose delivered to the
BS was significantly lower with IMRT when compared to
FSRT planning (Table 3). When assessing the percentage
of mean dose received by 50% of the volume of this
critical structure or the mean percentage of the minimum
dose, the computed doses to the BS were however not
significantly different with IMRT and FSRT planning
(Table 3; 77.1 vs 85.6%; P = 0.13 and 38.7 vs 67.4%;
P = 0.10, respectively). The supratentorial brain received
an inferior percentage of mean and minimum doses using
IMRT when compared to FSRT (Table 3). The percent-
age of maximum doses delivered to the brain were
however not different (mean, 84.4 vs 84.1%; P = 0.97;
Table 3).
Table 2 Treatment characteristics of non-conventional radiation
therapy
IMRT FSRTa
Patient (n) 3 4
Total dose (Gy)
Median 59.4 55.8
Range 59.4–60 55.8–59.4
Fractions (n)
Median 33 31
Range 30–33 31–33
Treatment duration (days)
Median 48 48
Range 46–50 46–52
Monitor units
Median 594 498
Range 532–880 451–544
Mean dose ± SD delivered to target volume (Gy)
Dmax 63.1 ± 1.1 58.8 ± 2.6
Dmin 51.3 ± 2.7 55.1 ± 1.1
D50 59.9 ± 0.5 56.9 ± 2.0
IMRT Intensity modulated radiotherapy, EBRT external beam radio-
therapy, FSRT fractionated stereotactic radiotherapy, Dmax mean
maximum dose, Dmin mean minimum dose, D50 mean dose for 50% of
tissue volume
a FSRT is delivered with external beam therapy (see text)
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Tumor control
One patient with a Grade III ependymoma who underwent
sub-total resection died before the start of IMRT because of
spinal metastatic spread of disease not diagnosed at the
moment of IMRT planning. At the last follow-up, no
patient presented a local or distant progression. The esti-
mated 3-year progression-free and OS rates were 85.7
and 100%, respectively. No second malignancies were
observed at last follow-up.
Toxicity
Intensity modulated radiation therapy and SFRT were well
tolerated during treatment. One patient could, however,
not start radiotherapy, as a result of her declining NFS.
She subsequently died shortly afterwards of uncontrolled
metastatic disease. All other patients completed the pre-
scribed course of RT without treatment interruptions and
with a median treatment time inferior than 50 days. The
most common acute side effects were grade 1 alopecia
or retro-auricular erythema. Stable KPS and NFS were
observed for all treated patients. No patient developed
acute grade 1 nausea and vomiting at the start of RT. No
acute grade [1 adverse events were observed for the six
treated patients.
During the follow-up, two patients presented hypoa-
cousia, of which one bilateral hearing dysfunction (grade 2)
was attributed to cisplatinum chemotherapy. Another
patient, not receiving chemotherapy, presented a unilateral
right hearing impairment (grade 2) after IMRT, despite the
absence of difference between the mean dose delivered to
right and left cochlea (D mean: 25 vs 25.5 Gy for right and
left cochlea, respectively). No radiation-induced hormone
deficiency, brain necrosis, myelitis, visual loss or neuro-
cognitive impairment were observed at the last follow-up.
Discussion
The estimated 3-year PFS rate of [85% compared favor-
ably with conventional RT series [15–17]. These data are
also in line with the IMRT study of Schroeder et al. [8],
reporting an identical outcome showed that IMRT can help
to improve local control without an increased risk of
marginal failure.
Current US protocols aim at delivering high dose (i.e.,
60 Gy) RT using conventional RT techniques only. These
techniques have been associated with substantial late
radiation-induced adverse events in malignant brain tumor
children at young ages. A recent series from Brazil has
shown undisputedly that the majority ([80%) of children
with brain tumors present a compromise speech, language
and hearing function, as a result of their illness and treat-
ment [18]. It is axiomatic that the less non-target brain
tissue is irradiated, such as the cochleae and pituitary
gland, the better the neuro-cognitive or endocrinological
function will be. Controlled use of IMRT and FSRT allows
one to achieve significant improvement in dose distribution
while sparing OARs, when compared to conventional RT.
We do not have the prescience to compare these two
radiation modalities with our limited number of patients,
although all published ependymoma series contain a
restricted number of subjects. There are unquestionably
several limitations of our study. First, the study design was
retrospective in nature and thus lacked complete data for
certain variables such as neurocognitive or quality of live
data. The small sample size of seven children limited the
statistical power to detect significant differences between
IMRT and FSRT parameters. Additionally, the differential
institutional treatment strategies and delivery techniques
limits the applicability of these data to patients treated with
non-conventional RT. This being said, and notwithstanding
these limitations, it is reasonable to make two observations.
Table 3 Comparison between IMRT and EBRT ? FSRT boost for mean maximum, minimum, and 50% of tissue volume doses (% of the total
prescribed dose) for organs at risk
IMRT FSRTa Pb
Dmax Dmin D50% Dmax Dmin D50%
Brainstem (Gy) 58.1 (97.5%) 23.1 (38.7%) 46.0 (77.1%) 58.9 (103.9%) 48.5 (67.4%) 48.5 (85.6%) 0.04
Cochleae (Gy) 35.4 (59.5%) 25.3 (42.5%) 29.0 (48.6%) 48.1 (85.0%) 45.2 (80.0%) 45.9 (81.2%) 0.05
Pituitary gland (Gy) 22.8 (38.2%) 13.3 (22.4%) 16.7 (28.2%) 11.3 (20.1%) 1.9 (3.3%) 3.6 (6.3%) 0.05
Optic chiasm (Gy) 22.7 (38.1%) 11.0 (18.5%) 14.0 (23.5%) 8.0 (14.1%) 2.3 (4.0%) 3.7 (6.6%) 0.001
Supratentorial brain (Gy) 50.3 (84.4%) 0 (0.0%) 6.2 (10.3%) 47.5 (84.1%) 0.2 (0.0%) 12.3 (21.7%) 0.97
IMRT Intensity modulated radiotherapy, EBRT external beam radiotherapy, FSRT fractionated stereotactic radiotherapy, Dmax mean maximum
dose, Dmin mean minimum dose, and D50% mean dose to 50% of tissue volume
a FSRT is delivered with external beam therapy (see text)
b Student’s t test, Dmax
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First, both techniques presented equivalent optimal tar-
get volume coverage but correlated with a different dose
distribution at OARs. While FSRT used after conventional
PF irradiation delivered less radiation to the OARs located
in the floor of the middle cranial fossa, such as the optic
chiasm and the pituitary gland, IMRT capitalized the
conformal ability to ‘paint’ the dose in the vicinity of
the brainstem and the cochleae (Table 3). However, the
increased cochlear irradiation in the FSRT group must
be considered with caution, as it results essentially from the
posterior fossa conventional RT course and not from
the FSRT contribution. Moreover, it has been suggested
that smaller radiation fields, when compared to more
comprehensive irradiation, are equi-effective in ependy-
moma [19], suggesting that the irradiation of the entire
posterior fossa may not be warranted for non-metastatic,
low-grade infratentorial ependymoma [20]. Thus, the
decision to irradiate the cerebellum before the FSRT boost
can bias the final dose distribution in this subgroup of
patients, allowing to a less optimal sparing of OARs than
that expected using FSRT alone.
Second, the number of MU necessary for the delivery
of 55–60 Gy was significantly higher with IMRT than
with FSRT (Table 2). The number of MU in IMRT is
function of the plan complexity. In essence, the more
complex the plan is, the longer the beam has to be turned
on, so as to optimally conform the dose to the target
volume by various delivery modalities (dynamic sequen-
tial arc or ‘step and shoot’ sliding windows techniques).
Using small, non-intensity modulated stereotactic fields
does not require, by definition, this photon-fluence mod-
ulation and thus a consequential increased number of MU.
Although the integral dose (i.e., dose outside the target
volume) increase is not solely due to the MU output but
also to the beam energy and machine collimator design, it
is a major concern in the pediatric population [21]. Using
pediatric-size anthropomorphic phantom, a dose compar-
ative study has shown that IMRT delivery resulted in
higher doses to distant points to the target when compared
to non-IMRT [22]. Consequently, using an IMRT delivery
in a pediatric population, an increased risk to develop
second radiation-induced malignancies is expected,
although no reports in this regard have been published in
the recent literature [23, 24]. The limited follow-up period
of the present series should caution us to develop any
zealotry about the lack of observed radiation-induced
tumors. During the carcinogenesis period, there is a latency
time between exposure to radiation and cancer onset. Thus,
longer observation time may be necessary to observe these
secondary malignancies.
Recently, different authors investigated the clinical
outcome and the evident dosimetric advantage of proton
beam radiation over photons in the treatment of intracranial
ependymoma [25, 26]. Nevertheless, it is important to
underline that the accessibility to proton centers is limited
worldwide and that IMRT and FSRT remain actually the
most widely diffused and accessible non-conventional
radiation techniques able to offer excellent results in the
treatment of pediatric tumors.
Conclusions
In conclusion, the clinical outcomes obtained with either
IMRT or FSRT compared favorably with the data of con-
ventional RT reported in the literature. These treatment
techniques are feasible and well tolerated, even in a very
young population. Dosimetrically, they appear to be similar
in terms of tumor coverage. The acute and late toxicities
were tolerable and comparable between IMRT and FSRT
despite a differential OARs irradiation. Further research
regarding radiation delivery with these techniques is jus-
tified in the framework of future dose-comparative and
clinical studies.
Conflict of interest None.
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